论文部分内容阅读
目的 评价吡柔比星(THP)膀胱内灌注预防浅表性膀胱癌术后复发的近期疗效。方法 对29例浅 表性膀胱癌患者行膀胱部分切除或经尿道膀胱肿瘤电切术,术后一周THP60mg作膀胱内灌注,每周1次共8次, 以后每月1次,共1年,每次药物在膀胱内保留1h。平均随访15个月。结果 无肿瘤复发28例,复发1例,复发 率为3.4%。不良反应者8例(27.5%),均为不同程度膀胱刺激症状。结论 THP膀胱内灌注预防浅表性膀胱癌 术后复发近期效果满意,副作用小,耐受性良好。
Objective To evaluate the short-term efficacy of intravesical instillation of pirarubicin (THP) in preventing postoperative recurrence of superficial bladder cancer. Methods Twenty-nine patients with superficial bladder cancer underwent resection of bladder or transurethral resection of bladder tumor. One week after THP60mg intravesical instillation, once a week for a total of 8 times and once a month for 1 year, Each time the drug remains in the bladder 1h. The average follow-up of 15 months. No tumor recurrence in 28 cases, 1 case of recurrence, the recurrence rate was 3.4%. Adverse reactions in 8 cases (27.5%), are varying degrees of bladder irritation. Conclusion Intravesical instillation of THP is effective in preventing postoperative recurrence of superficial bladder cancer with less side effects and good tolerability.